This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy

LUX-Lung 3 clinical data
XOVOLTIB® is the first targeted therapy to demonstrate a significant 1st-line OS benefit versus chemotherapy in del19 (exon 19) patients1-3

LUX-Lung 3: Overall survival (secondary endpoint)
Preplanned subgroup analysis

XOVOLTIB® significantly extended 1st-line OS by over 1 year versus pemetrexed/cisplatin in subgroup of del19 patients1

  • 46% reduction in relative risk of death in del19 patients  (HR=0.54; P=0.0015)1
  • In LUX-Lung 3, median OS was 33.3 and 21.1 months for XOVOLTIB® versus pemetrexed/cisplatin, respectively (HR=0.54; 95% CI, 0.36–0.79; P=0.0015)1

CI=confidence interval; HR=hazard ratio; OS=overall survival.

LUX-Lung 6 clinical data
XOVOLTIB® significantly extended 1st-line OS by over 1 year versus gemcitabine/cisplatin in subgroup of del19 patients1

LUX-Lung 6: Overall survival (secondary endpoint)
Preplanned subgroup analysis

  • 36% reduction in relative risk of death in del19 patients (HR=0.64; P=0.023)1
  • In LUX-Lung 6, median OS was 31.4 and 18.4 months for XOVOLTIB® versus gemcitabine/cisplatin, respectively (HR=0.64; 95% CI, 0.44–0.94; P=0.023)1

CI=confidence interval; HR=hazard ratio; OS=overall survival.

You may be interested in:

Is this information compelling to you?

References

  1. Yang JC et al. Lancet Oncol. 2015;16(2):141-151.
  2. Fukuoka M et al. J Clin Oncol. 2011;29:2866-2874.
  3. Khozin S et al. Oncologist. 2014;19(7):774-779.
  1. [1] Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.

  2. [2] Wu YL et al. Lancet Oncol. 2014;15(2):213-222.

  3. [3] Yang JC et al. Lancet Oncol. 2015;16(2):141-151.

  4. [4] Park K et al. Lancet Oncol. 2016;17(5):577-589.

  5. [5] Soria JC et al. Lancet Oncol. 2015;16(8):897-907.

  6. [6] Solca F et al. J Pharmacol Exp Ther. 2012;343(2):342-350.

  7. [7] Yang JC et al. J Clin Oncol. 2013;31(27):3342-3350.

  8. [8] Hirsch V et al. Poster #369 presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, USA; 3-7 June 2016.

  9. [9] Yang JCH et al. Ann Oncol. 2016;27(11):2103-2110.

  10. [10] Schuler M et al. J Thorac Oncol. 2016;11(3):380-390.

  11. [11] Paz-Arez L et al. Ann Oncol. 2017; 28(2):270-277

  12. [12] XOVOLTIB® Local pack insert version dated 21st July 2017

In case you come across any adverse events related to our products, please report it to PV team immediately.
Phone: +91 9819241697
Email: PV_local_India@boehringer-ingelheim.com

For any query on Boehringer Ingelheim India's product or therapy area, kindly contact
Phone: 1800227887
Email: medical.query.mum@boehringer-ingelheim.com

Back to top